Peer-reviewed publications:
(2021-present)
64. Wang L, Bi S, Li Z, Liao A, Li Y, Yang L, Zhou X, Gao Y, Liu X, Zou Y, Zhang X, Shi J, Yu S, Yu Z*, Guo J*. Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy. Biomaterials 2025, 313: 122766.（中科院1区；影响因子12.8）
63. Yu Z, Huang L, Guo J*. Anti-stromal nanotherapeutics for hepatocellular carcinoma. Journal of Controlled Release 2024, 367: 500-514.（中科院1区；影响因子10.5）
62. Wang L#, Yu Z#, Zhang J*, Guo J*. Nanoformulations of chemotherapeutic activators for cGAS-STING pathway in tumor chemoimmunotherapy. Drug Discovery Today 2024, 29: 103892.（中科院2区；影响因子6.5）
61. Cao C, Li Y, Shi F, Jiang S, Li Y, Yang L, Zhou X, Gao Y, Tang F, Li H, Han S, Yu Z, Zou Y*, Guo J*. Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma. International Journal of Pharmaceutics 2024, 661: 124424.（中科院2区Top；影响因子5.3）
60. Wang M, Rousseau B, Qiu K, Huang G, Zhang Y, Su H, Le Bihan-Benjamin C, Khati I, Artz O, Foote MB, Cheng YY, Lee KH, Miao MZ, Sun Y, Bousquet PJ, Hilmi M, Dumas E, Hamy AS, Reyal F, Lin L, Armistead PM, Song W, Vargason A, Arthur JC, Liu Y, Guo J, Zhou X, Nguyen J, He Y, Ting JP, Anselmo AC, Huang L. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nature Biotechnology 2024, 42: 1263-1274.（中科院1区；影响因子33.1）
59. Yu Z#*, Zou Y#, Han S#, Sun D#, Wang L, Yang L, Li Y, Zhang X, Guo J*. Lenalidomide promotes melarsoprol-activated cGAS-STING-mediated immunotherapy for hepatocellular carcinoma via attenuating TNF-α activity. Fundamental Research 2023, DOI: 10.1016/j.fmre.2023.05.013.（ESCI）
58. Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, Liao A, Zhang X, Jiang X, Liang D, Dai Y, Zheng QC, Yu Z*, Guo J*. D-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Science Advances 2023, 9: eadg2697.（中科院1区；影响因子11.7）
57. Chu D, Chen J, Liu X, Liao A, Song X, Li Y, Yang L, Chen Z, Yu Z, Guo J*. A tetramethylpyrazine-loaded hyaluronic acid-based hydrogel modulates macrophage polarization for promoting wound recovery in diabetic mice. International Journal of Biological Macromolecules 2023, 245: 125495.（中科院1区；影响因子7.7）
56. Sun Y, Cronin MF, Mendonca MCP, Guo J*, O’Driscoll CM*. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumour Microenvironment for Prostate Cancer Therapy. Molecular Pharmaceutics 2023, 20: 5921-5936.（中科院2区；影响因子4.5）
55. Sun Y, Cronin MF, Mendonca MCP, Guo J*, O’Driscoll CM*. Sialic Acid-Targeted Cyclodextrin-Based Nanoparticles Deliver CSF-1R siRNA and Reprogram Tumour-Associated Macrophages for Immunotherapy of Prostate Cancer. European Journal of Pharmaceutical Sciences 2023, 185: 106427.（中科院2区；影响因子4.3）
54. Li L*, Zou Y, Wang L, Yang L, Li Y, Liao A, Chen Z, Yu Z, Guo J, Han S*. Nanodelivery of scutellarin induces immunogenic cell death for treating hepatocellular carcinoma. International Journal of Pharmaceutics 2023, 642: 123114.（中科院2区Top；影响因子5.3）
53. 李萌，余玲玲，邱新云，汪文昱，胡兵，韩淑兰，邹宜芳*，郭建锋*。载槲皮素仿生纳米粒诱导结直肠癌细胞凋亡的研究。上海中医药大学学报 2023, DOI: 10.16306/j.1008‐861x.2023.01.001.
52. Li YN, Shi X, Sun D, Han S, Zou Y, Wang L, Yang L, Li Y, Shi Y*, Guo J*, O’Driscoll CM. Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma. International Journal of Pharmaceutics 2023, 636:122791.（中科院2区Top；影响因子5.3）
51. Guo J#*, Zou Y#, Huang L*. Nano delivery of chemotherapeutic ICD inducers for tumor immunotherapy. Small Methods 2023, 7: e2201307.（中科院2区；影响因子10.7）
50. Guo J, Huang L*. Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. Nature Protocols 2022, 17: 1818-1831.（中科院1区；影响因子13.1）
49. Han S, Bi S, Guo T, Sun D, Zou Y, Wang L, Song L, Chu D, Liao A, Song X, Yu Z*, Guo J*. Nano co-delivery of plumbagin and dihydrotanshinone I reverses immunosuppressive TME of liver cancer. Journal of Controlled Release 2022, 348: 250-263.（中科院1区；影响因子10.5）
48. Wang L#, Xia K#, Han L, Zhang M, Fan J, Song L, Liao A, Wang W*, Guo J*. Local administration of Ginkgolide B using a hyaluronan-based hydrogel improves wound healing in diabetic mice. Frontiers in Bioengineering & Biotechnology 2022, 10: 898231.（中科院2区；影响因子4.3）
47. Guo J*, Huang L*. Nanodelivery of cGAS-STING activators for tumor immunotherapy. Trends in Pharmacological Sciences 2022, 43: 957-972.（中科院1区；影响因子13.9）
46. Yu Z, Li Y, Li Y, Zhang J, Li M, Ji L, Tang Y, Zhang Y, Sheng J, Han Q, Li F, Guo J, Wang L, Sun X*, Gao Y*, Feng H*. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 2022, 10: e004297.（中科院2区；影响因子10.3）
45. Yu Z, Guo J, Liu Y, Wang L, Liu Z, Gao Y, Huang L*. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. Journal of Nanobiotechnology 2022, 20: 9.（中科院1区；影响因子10.6）
44. Song L#, Yang H#, Liang D#, Chu D, Yang L, Li M, Yang B, Shi Y, Chen Z, Yu Z, Guo J*. A chlorogenic acid-loaded hyaluronic acid-based hydrogel facilitates anti-inflammatory and pro-healing effects for diabetic wounds. Journal of Drug Delivery Science and Technology 2022, 70: 103232.（中科院3区；影响因子4.5）
43. Sun D, Zou Y, Song L, Han S, Yang H, Chu D, Dai Y, Ma J, O’Driscoll CM, Yu Z*, Guo J*. A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer. Acta Pharmaceutica Sinica B 2022, 12: 378-393.（中科院1区；影响因子14.7）
42. Jin F*, Li J, Guo J, Doeppner TR, Hermann DM, Yao G*, Dai Y*. Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. European Heart Journal Open 2021, DOI: 10.1093/ehjopen/oeab022.
41. Yang H#, Song L#, Sun B, Chu D, Yang L, Li M, Li H, Dai Y, Yu Z, Guo J*. Modulation of macrophages by a paeoniflorin-loaded hyaluronic acid-based hydrogel promotes diabetic wound healing. Materials Today Bio 2021, 12: 100139.（中科院1区；影响因子8.7）
40. Zou Y#, Xiao F#, Song L, Sun B, Sun D, Chu D, Wang L, Han S, Yu Z, O’Driscoll CM*, Guo J*. A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer. International Journal of Pharmaceutics 2021, 606: 120888.（中科院2区Top；影响因子5.3）
39. 韩淑兰，段昊雨，孙丹丹，宋柳，邹宜芳，初迪，李欢*，郭建锋*。白花丹素对肝癌细胞增殖迁移凋亡能力的影响及其作用机制研究。特产研究 2021, DOI: 10.16720/j.cnki.tcyj.2021.128.
38. 孙丹丹，邹宜芳，宋柳，杨浩，初迪，韩淑兰，刘昕*，郭建锋*。人参皂苷Rg3诱导结直肠癌细胞凋亡作用研究。特产研究 2021, DOI: 10.16720/j.cnki.tcyj.2021.051.
37. Guo J, Yu Z, Sun D, Zou Y, Liu Y, Huang L*. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Molecular Cancer 2021, 20:10.（中科院1区；影响因子27.7）
36. Sun D#, Zhang J#, Wang L, Yu Z, O’Driscoll CM, Guo J*. Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy. Drug Discovery Today 2021, 26: 651-662.（中科院2区；影响因子6.5）
35. Yang H, Song L, Zou Y, Sun D, Wang L, Yu Z, Guo J*. Role of hyaluronic acids and potential as regenerative biomaterials in wound healing. ACS Applied Bio Materials 2021, 4: 311-324.（ESCI）
(2016-2020)
34. Yang Y, Guo J*, Huang L*. Tackling TAMs for cancer immunotherapy: It's nano time. Trends in Pharmacological Sciences 2020, 41: 701-714.（中科院1区；影响因子13.9）
33. Guo J, Huang L*. Membrane-core nanoparticles for cancer nanomedicine. Advanced Drug Delivery Reviews 2020, 156: 23-39.（中科院1区；影响因子15.2）
32. Guo J, Yu Z, Das M, Huang L*. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 2020, 14: 5075-5089.（中科院1区；影响因子15.8）
31. Liu Y, Guo J*, Huang L*. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics 2020, 10: 3099-3117.（中科院1区；影响因子12.4）
30. Yu Z, Guo J, Hu M, Gao Y, Huang L*. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. ACS Nano 2020, 14: 4816-4828.（中科院1区；影响因子15.8）
29. Wang L, Pei J*, Cong Z, Zou Y, Sun T, Davitt F, Garcia-Gil A, Holmes JD, O’Driscoll CM, Rahme K, Guo J*. Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumor-bearing mice. International Journal of Nanomedicine 2019, 14: 1817-1833.（中科院2区Top；影响因子6.6）
28. Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O’Driscoll CM, Guo J*. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice. European Journal of Pharmaceutics and Biopharmaceutics 2019, 137: 56-67.（中科院2区Top；影响因子4.4）
27. Gao Y#, Sun Y#, Yang H, Qiu P, Cong Z, Zou Y, Song L, Guo J*, Anastassiades, TP. A low molecular weight hyaluronic acid derivative accelerates excisional wound healing by modulating pro-Inflammation, promoting epithelialization and neovascularization, and remodeling collagen. International Journal of Molecular Sciences 2019, 20: 3722.（中科院2区Top；影响因子4.9）
26. Rahme K*, Guo J*, Holmes JD. Bioconjugated gold nanoparticles enhance siRNA delivery in prostate cancer cells. Methods in Molecular Biology 2019, 1974: 291-301.
25. Zhang Z, Song L, Guo J*. The application of pre-clinical animal models to optimise nanoparticulate drug delivery for hepatocellular carcinoma. Pharmaceutical Nanotechnology 2018, 6: 221-231.
24. Guo J*, Luan X, Cong Z, Sun Y, Wang L, McKenna SL, Cahill MR, O’Driscoll CM*. The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. Journal of Controlled Release 2018, 286: 154-166.（中科院1区；影响因子10.5）
23. Guo J*, Rahme K, He Y, Li L, Holmes JD, O’Driscoll CM*. Gold nanoparticles enlighten the future of cancer theranostics. International Journal of Nanomedicine 2017, 12: 6131-6152.（中科院2区Top；影响因子6.6）
22. Guo J, Schlich M, Cryan JF, O’Driscoll CM*. Targeted drug delivery via folate receptors for the treatment of brain cancer: can the promise deliver. Journal of Pharmaceutical Sciences 2017, 106: 3413-3420.（中科院3区；影响因子3.7）
21. Guo J*, Russell EG, Darcy R, Cotter TG, McKenna SL, Cahill MR, O’Driscoll CM*. Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukaemia - physicochemical characteristics, in vitro mechanistic studies and ex vivo patient derived therapeutic efficacy. Molecular Pharmaceutics 2017, 14: 940-952.（中科院2区；影响因子4.5）
20. Evans JC, Malhotra M, Fitzgerald KA, Guo J, Cronin MF, Curtin CM, O’Brien FJ, Darcy R, O’Driscoll CM*. Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3D prostate cancer bone metastases model. Molecular Pharmaceutics 2017, 14: 42-52.（中科院2区；影响因子4.5）
19. Guo J*, O’Driscoll CM, Holmes JD, Rahme K*. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells. International Journal of Pharmaceutics 2016, 509: 16-27.（中科院2区Top；影响因子5.3）
18. Russell EG#, Guo J#, O’Sullivan EC, O’Driscoll CM, McCarthy FO, Cotter TG*. 7-Formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice. Investigational New Drugs 2016, 34: 15-23.（中科院3区；影响因子3）
17. Evans JC, Malhotra M, Guo J, O’Shea JP, Hanrahan K, O’Neill A, Landry W, Griffin BT, Darcy R, Watson RW, O’Driscoll CM*. Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitroand prolonged circulation in vivo. Nanomedicine 2016, 12: 2341-2351.（中科院3区；影响因子4.7）
16. Fitzgerald KA, Rahme K, Guo J, Holmes JD, O’Driscoll CM. Anisamide-targeted gold nanoparticles for prostate cancer therapy - synthesis, physicochemical characterisation and in vitro evaluation. Journal of Materials Chemistry B 2016, 4: 2242-2252.（中科院2区Top；影响因子6.1）
15. Griffin BT, Guo J, Presas E, Donovan MD, Alonso MJ, O’Driscoll CM. Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Advanced Drug Delivery Reviews 2016, 106: 367-380.（中科院1区；影响因子15.2）
14. Fitzgerald KA, Guo J, Raftery RM, Castano IM, Curtin CM, Gooding M, Darcy R, O’Brien FJ, O’Driscoll CM. Nanoparticle-mediated siRNA delivery assessed in a 3D co-culture model simulating prostate cancer bone metastasis. International Journal of Pharmaceutics 2016, 511: 1081069.（中科院2区Top；影响因子5.3）
13. Guo J, McKenna SL, O’Dwyer ME, Cahill MR, O’Driscoll CM*. RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opinion on Therapeutic Targets 2016, 20: 107-121.（中科院2区；影响因子4.6）
(2010-2015)
12. Guo J, Rahme K, Fitzgerald KA, Holmes JD, O’Driscoll CM*. Biomimetic gold nanocomplexes for gene knockdown: Will gold deliver dividends for small interfering RNA nanomedicines. Nano Research 2015, 8: 3111-3140.（中科院1区；影响因子9.5）
11. Guo J, Armstrong M, O’Driscoll CM, Holmes JD, Rahme K*. Positively charged, surfactant-free gold nanoparticles for nucleic acid delivery. RSC Advances 2015, 5: 17862-17871.（中科院3区；影响因子3.9）
10. Rahme K#, Guo J#, Holmes JD, O’Driscoll CM*. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery. Colloids and Surfaces B: Biointerfaces 2015, 135: 604-612.（中科院2区Top；影响因子5.4）
9. Fitzgerald KA, Guo J, Tierney EG, Curtin C, Malhotra M, O’Brien FJ, O’Driscoll CM*. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics. Biomaterials 2015, 66: 53-66.（中科院1区；影响因子12.8）
8. Guo J, Cahill MR, McKenna SL, O’Driscoll CM*. Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. Biotechnology Advances 2014, 32: 1396-1409.（中科院1区；影响因子12.1）
7. Fitzgerald, KA, Evans, JC, McCarthy J, Guo J, Prencipe M, Kearney M, Watson WR, O’Driscoll CM*. The role of transcription factors in prostate cancer and potential for future RNA interference therapy. Expert Opinion on Therapeutic Targets 2014, 18: 633-649.（中科院2区；影响因子4.6）
6. Guo J, Evans J, O’Driscoll CM*. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer. Trends in Molecular Medicine 2013, 19: 250-261.（中科院1区；影响因子12.8）
5. Guo J, O’Mahony AM, Cheng WP, O’Driscoll CM*. Amphiphilic polyallylamine based polymeric micelles for siRNA delivery to the gastrointestinal tract: In vitro investigations. International Journal of Pharmaceutics 2013, 447: 150-157.（中科院2区Top；影响因子5.3）
4. Guo J, Ogier J, Desgrangers S, Darcy R, O’Driscoll C*. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 2012, 33: 7775-7784.（中科院1区；影响因子12.8）
3. Guo J, Cheng WP, Gu J, Ding C, Qu X, Yang Z, O’Driscoll C*. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-l-lysine nanocarrier to suppress prostate cancer growth in mice. European Journal of Pharmaceutical Sciences 2012, 45: 521-532.（中科院2区；影响因子4.3）
2. Guo J#, Bourre L#, Soden DM, O’Sullivan GC, O’Driscoll C*. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics. Biotechnology Advances 2011, 29: 402-417.（中科院1区；影响因子12.1）
1. Guo J#, Fisher KA#, Darcy R, Cryan JF, O’Driscoll C*. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Molecular Biosystems 2010, 6: 1143-1161.（影响因子3.3）